title: YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis.
authors: Yasutomo
authors: Y
authors: Imai
authors: Seiko
authors: S
authors: Aochi
authors: Keiji
authors: K
authors: Iwatsuki
authors: Hajime
authors: H
authors: Sano
authors: Kiyofumi
authors: K
authors: Yamanishi
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000097:blood* / Q000188:drug therapy; D001324:Autoantigens / Q000097:blood*; D015415:Biomarkers / Q000097:blood*; D000071451:Chitinase-3-Like Protein 1; D005260:Female; D006801:Humans; D000069285:Infliximab; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D054392:Adipokines; D000911:Antibodies, Monoclonal; D001324:Autoantigens; D015415:Biomarkers; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D037102:Lectins; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab